Clearside Overview Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. Quarterly Summary Show all Latest Quarterly Results Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update Clearside Biomedical Q1 2022 Financial Results and Corporate Update Call Form 10-Q View All News Releases May 11 2022 Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update May 5 2022 Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology Apr 29 2022 Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022 View All Events Clearside Biomedical Q1 2022 Financial Results and Corporate Update Call May 11, 2022 at 4:30 PM EDT Needham Virtual Healthcare Conference Apr 13, 2022 at 3:45 PM EDT 34th Annual ROTH Conference Mar 14 - Mar 15, 2022 View All Stock Quote Change Volume 52 Week High 52 Week Low May 18, 2022 8:06 PM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.